DexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the ...

The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

View our complete analysis and fair value estimate and you decide. NasdaqGS:DXCM Earnings Per Share Growth as at Mar 2025 AI is about to change healthcare. These 23 stocks are working on ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NexGel Inc (NXGL – Research Report) and Dexcom ...

DexCom (DXCM) announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for ...

Shares of DexCom Inc. DXCM rallied 3.79% to $73.38 Wednesday, on what proved to be an all-around positive trading session for ...

DexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the approval of the company’s upcoming 15-day G7 continuous glucose monitor (CGM).

Deep-pocketed investors have adopted a bearish approach towards DexCom (NASDAQ:DXCM), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...